The Day In Review: Biotech Falls Despite Genentech

October 11, 2005. Following its Q3 report yesterday, Genentech traded higher all day and closed up $2.59 at $84.59, a rise of 3.2%. But the strength in the giant biotech was not enough to overcome weakness elsewhere in the sector, and biotech ended lower on the day. The Centient Biotech 200 was down 17 points at 3619.50, a loss of .48%. Genaera released positive preliminary data on Evizon, its blindness treatment, Wyeth will close its estrogen replacement manufacturing plant, Vical will begin a Phase II trial of HIV vaccine, Praecis Pharma will sell its headquarters and research facility to raise cash, and BioCryst keeps climbing as fears of avian flu escaltate.